• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    9/11/23 1:33:44 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    SC 13G/A 1 tv0023-elancoanimalhealthinc.htm SCHEDULE 13G/A elancoanimalhealthinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 4)*

    Name of issuer:  Elanco Animal Health Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  28414H103

    Date of Event Which Requires Filing of this Statement: August 31, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  28414H103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    268,362

    7.  SOLE DISPOSITIVE POWER

    48,212,704

    8.  SHARED DISPOSITIVE POWER

    1,094,934

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    49,307,638

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.01%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Elanco Animal Health Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2500 Innovation Way
    Greenfield, IN 46140

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    28414H103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  September 11, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ELAN
    SEC Filings

    View All

    SEC Form 144 filed by Elanco Animal Health Incorporated

    144 - Elanco Animal Health Inc (0001739104) (Subject)

    8/11/25 3:58:15 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Elanco Animal Health Incorporated

    10-Q - Elanco Animal Health Inc (0001739104) (Filer)

    8/7/25 9:05:13 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    8/7/25 6:27:18 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs

    The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the worldLaunch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission. This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a signific

    7/24/25 5:42:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:55:46 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:54:06 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/29/25 4:24:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/11/25 5:13:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/7/25 4:21:21 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/26/24 5:05:35 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Elanco Animal Health from Market Perform to Outperform and set a new price target of $18.00

    7/17/25 7:51:30 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by William Blair

    William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform

    6/26/25 7:49:03 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Elanco Animal Health with a new price target

    UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

    12/9/24 7:40:18 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

    GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

    5/28/25 7:25:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Strengthens Board of Directors with Addition of Stacey Ma

    Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

    11/12/24 8:33:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports First Quarter 2025 Results

    Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

    5/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care